Acute Myeloid Leukemia Market Forecast (2024-2031), Size
The Acute Myeloid Leukemia Market is expected to register a CAGR of 5.50% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The report presents an analysis based on by by drug class (tyrosine kinase inhibitors, hedgehog pathway inhibitors, topoisomerase 2 inhibitors, and others). The report further provides analysis based on end use (hospital, clinic, and others). The global analysis is further broken-down at regional level and major countries. The market size and forecast at global, regional, and country levels for all the key market segments are covered under the scope. The report offers the value in USD for the above analysis and segments. The report provides key statistics on the market status of the key market players and offers market trends and opportunities.
Purpose of the ReportThe report Acute Myeloid Leukemia Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Acute Myeloid Leukemia Market Segmentation
Drug Class- Tyrosine Kinase Inhibitors
- Hedgehog Pathway Inhibitors
- Topoisomerase 2 Inhibitors
- Others
- Hospital
- Clinic
- Others
Strategic Insights
Acute Myeloid Leukemia Market Growth Drivers- Increasing cases of acute myeloid leukemia (AML): A major driver for growth in the market has been the increasing global incidence rates of AML. This incidence is influenced by the increasing population, which has reached advanced ages, and lifestyle risk factors leading to an increasing demand for effective therapies and investment in healthcare for the management of AML cases.
- Investment in Research and Development: This is the reason for the market growth of acute myeloid leukemia drug markets. Pharmaceutical companies are continuously investing significant resources in developing new systems for research and development. Likewise, clinical trials about the future of possible new treatment options and sets of improvements of current therapies are progressing. These will keep encouraging increasing innovative adoption of AML treatment.
- Emerging Treatment Possibilities:Progress in treatment paradigms such as targeted therapy and immunotherapy is likely to make a profound impact on patient prognosis in AML. Development of CAR-T cell therapy and novel drug combinations that improve survival provides new avenues for therapy and growth to the overall market.
- Personalizing medicines: This trend towards personalizing medicines is catching on in the AML market. Personalization, through knowing what individual genes are up to in the system, allows one to come to know how therapies can be better targeted with consequent improvements in poor-to-no side effects for the person. It is only expected that this technique would thrive more and become the trend in the management concerning AML.
- Emerging Telemedicine: Emerging telehealth and mobile health technologies transform the care provision of highly symptomatic AML patients-from patient conditions to virtually nonexistent and unsupported telecommunication connections-nonsupported telecommunication connections along with low use of patients. This automated system may also track and record real-time events of patient care and medication adherence.
- Pairing Therapies is increasing: There has been visible growth in the trend of combination therapies using multiple treatment modalities for AML. Combination of targeted therapy along with traditional chemotherapy or immunotherapy has been expected to improve the efficacy of the treatment along with minimization of resistance to give a very comprehensive approach to managing this complicated disease.
- Innovative Therapies Development: Investing in research and development activities for the discovery and development of new therapeutic molecules focusing on aberrant genetic modifications found in AML patients holds fantastic opportunities for funding. It would offer great potentials in differentiating products from others in the competitive arena, as well as catering to unmet medical needs in diverse patient groups.
- Clinical Trials and Emerging Therapies: The increasing importance given to clinical trials for new AML therapies is already part of the market scenario. As regulatory bodies streamline the approval of such innovative therapies, the legislation encourages manufacturers to invest more time in research leading to the successful launch of new drugs, thus increasing competition in the market.
- Emerging Markets:All Manufacturers have emerging market opportunities for expansion as the incidences of AML are here on the up-rise. Affordable tailored treatments would thus enable companies to collect underserved populations and boost their market growth.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Acute Myeloid Leukemia Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Acute Myeloid Leukemia Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Rising cancer cases is the major factors boosting the acute myeloid leukemia market growth
The market is expected to grow at a CAGR of 9.6%
North America region accounts for highest revenue share acute myeloid leukemia market
The final report will duly include market size and projection estimates for all the segments from 2021 to 2031, along with a revenue share and compound annual growth rate (%) for the regional
/
country-wise market wherein 2021-2022 are the historic years, 2023 is considered to be the base year, and the forecast will be provided till 2031, along with CAGR (%)
Merck, Junshi Pharma,Cohereus Biosciences, Aditya Pharma, Genetech,Bristols Meyers Squibb,Top Alliance
Asia Pacific is estimated to grow at the highest CAGR over the forecast year (2023 - 2031)
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Acute Myeloid Leukemia Market - By Drug Class
1.3.2 Acute Myeloid Leukemia Market - By End Use
1.3.3 Acute Myeloid Leukemia Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ACUTE MYELOID LEUKEMIA MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ACUTE MYELOID LEUKEMIA MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ACUTE MYELOID LEUKEMIA MARKET - GLOBAL MARKET ANALYSIS
6.1. ACUTE MYELOID LEUKEMIA - GLOBAL MARKET OVERVIEW
6.2. ACUTE MYELOID LEUKEMIA - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. ACUTE MYELOID LEUKEMIA MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. TYROSINE KINASE INHIBITORS
7.3.1. Overview
7.3.2. Tyrosine Kinase Inhibitors Market Forecast and Analysis
7.4. HEDGEHOG PATHWAY INHIBITORS
7.4.1. Overview
7.4.2. Hedgehog Pathway Inhibitors Market Forecast and Analysis
7.5. TOPOISOMERASE 2 INHIBITORS
7.5.1. Overview
7.5.2. Topoisomerase 2 Inhibitors Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. ACUTE MYELOID LEUKEMIA MARKET - REVENUE AND FORECASTS TO 2028 - END USE
8.1. OVERVIEW
8.2. END USE MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL
8.3.1. Overview
8.3.2. Hospital Market Forecast and Analysis
8.4. CLINIC
8.4.1. Overview
8.4.2. Clinic Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. ACUTE MYELOID LEUKEMIA MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Acute Myeloid Leukemia Market Overview
9.1.2 North America Acute Myeloid Leukemia Market Forecasts and Analysis
9.1.3 North America Acute Myeloid Leukemia Market Forecasts and Analysis - By Drug Class
9.1.4 North America Acute Myeloid Leukemia Market Forecasts and Analysis - By End Use
9.1.5 North America Acute Myeloid Leukemia Market Forecasts and Analysis - By Countries
9.1.5.1 United States Acute Myeloid Leukemia Market
9.1.5.1.1 United States Acute Myeloid Leukemia Market by Drug Class
9.1.5.1.2 United States Acute Myeloid Leukemia Market by End Use
9.1.5.2 Canada Acute Myeloid Leukemia Market
9.1.5.2.1 Canada Acute Myeloid Leukemia Market by Drug Class
9.1.5.2.2 Canada Acute Myeloid Leukemia Market by End Use
9.1.5.3 Mexico Acute Myeloid Leukemia Market
9.1.5.3.1 Mexico Acute Myeloid Leukemia Market by Drug Class
9.1.5.3.2 Mexico Acute Myeloid Leukemia Market by End Use
9.2. EUROPE
9.2.1 Europe Acute Myeloid Leukemia Market Overview
9.2.2 Europe Acute Myeloid Leukemia Market Forecasts and Analysis
9.2.3 Europe Acute Myeloid Leukemia Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Acute Myeloid Leukemia Market Forecasts and Analysis - By End Use
9.2.5 Europe Acute Myeloid Leukemia Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Acute Myeloid Leukemia Market
9.2.5.1.1 Germany Acute Myeloid Leukemia Market by Drug Class
9.2.5.1.2 Germany Acute Myeloid Leukemia Market by End Use
9.2.5.2 France Acute Myeloid Leukemia Market
9.2.5.2.1 France Acute Myeloid Leukemia Market by Drug Class
9.2.5.2.2 France Acute Myeloid Leukemia Market by End Use
9.2.5.3 Italy Acute Myeloid Leukemia Market
9.2.5.3.1 Italy Acute Myeloid Leukemia Market by Drug Class
9.2.5.3.2 Italy Acute Myeloid Leukemia Market by End Use
9.2.5.4 Spain Acute Myeloid Leukemia Market
9.2.5.4.1 Spain Acute Myeloid Leukemia Market by Drug Class
9.2.5.4.2 Spain Acute Myeloid Leukemia Market by End Use
9.2.5.5 United Kingdom Acute Myeloid Leukemia Market
9.2.5.5.1 United Kingdom Acute Myeloid Leukemia Market by Drug Class
9.2.5.5.2 United Kingdom Acute Myeloid Leukemia Market by End Use
9.2.5.6 Rest of Europe Acute Myeloid Leukemia Market
9.2.5.6.1 Rest of Europe Acute Myeloid Leukemia Market by Drug Class
9.2.5.6.2 Rest of Europe Acute Myeloid Leukemia Market by End Use
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Acute Myeloid Leukemia Market Overview
9.3.2 Asia-Pacific Acute Myeloid Leukemia Market Forecasts and Analysis
9.3.3 Asia-Pacific Acute Myeloid Leukemia Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Acute Myeloid Leukemia Market Forecasts and Analysis - By End Use
9.3.5 Asia-Pacific Acute Myeloid Leukemia Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Acute Myeloid Leukemia Market
9.3.5.1.1 Australia Acute Myeloid Leukemia Market by Drug Class
9.3.5.1.2 Australia Acute Myeloid Leukemia Market by End Use
9.3.5.2 China Acute Myeloid Leukemia Market
9.3.5.2.1 China Acute Myeloid Leukemia Market by Drug Class
9.3.5.2.2 China Acute Myeloid Leukemia Market by End Use
9.3.5.3 India Acute Myeloid Leukemia Market
9.3.5.3.1 India Acute Myeloid Leukemia Market by Drug Class
9.3.5.3.2 India Acute Myeloid Leukemia Market by End Use
9.3.5.4 Japan Acute Myeloid Leukemia Market
9.3.5.4.1 Japan Acute Myeloid Leukemia Market by Drug Class
9.3.5.4.2 Japan Acute Myeloid Leukemia Market by End Use
9.3.5.5 South Korea Acute Myeloid Leukemia Market
9.3.5.5.1 South Korea Acute Myeloid Leukemia Market by Drug Class
9.3.5.5.2 South Korea Acute Myeloid Leukemia Market by End Use
9.3.5.6 Rest of Asia-Pacific Acute Myeloid Leukemia Market
9.3.5.6.1 Rest of Asia-Pacific Acute Myeloid Leukemia Market by Drug Class
9.3.5.6.2 Rest of Asia-Pacific Acute Myeloid Leukemia Market by End Use
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Acute Myeloid Leukemia Market Overview
9.4.2 Middle East and Africa Acute Myeloid Leukemia Market Forecasts and Analysis
9.4.3 Middle East and Africa Acute Myeloid Leukemia Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Acute Myeloid Leukemia Market Forecasts and Analysis - By End Use
9.4.5 Middle East and Africa Acute Myeloid Leukemia Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Acute Myeloid Leukemia Market
9.4.5.1.1 South Africa Acute Myeloid Leukemia Market by Drug Class
9.4.5.1.2 South Africa Acute Myeloid Leukemia Market by End Use
9.4.5.2 Saudi Arabia Acute Myeloid Leukemia Market
9.4.5.2.1 Saudi Arabia Acute Myeloid Leukemia Market by Drug Class
9.4.5.2.2 Saudi Arabia Acute Myeloid Leukemia Market by End Use
9.4.5.3 U.A.E Acute Myeloid Leukemia Market
9.4.5.3.1 U.A.E Acute Myeloid Leukemia Market by Drug Class
9.4.5.3.2 U.A.E Acute Myeloid Leukemia Market by End Use
9.4.5.4 Rest of Middle East and Africa Acute Myeloid Leukemia Market
9.4.5.4.1 Rest of Middle East and Africa Acute Myeloid Leukemia Market by Drug Class
9.4.5.4.2 Rest of Middle East and Africa Acute Myeloid Leukemia Market by End Use
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Acute Myeloid Leukemia Market Overview
9.5.2 South and Central America Acute Myeloid Leukemia Market Forecasts and Analysis
9.5.3 South and Central America Acute Myeloid Leukemia Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Acute Myeloid Leukemia Market Forecasts and Analysis - By End Use
9.5.5 South and Central America Acute Myeloid Leukemia Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Acute Myeloid Leukemia Market
9.5.5.1.1 Brazil Acute Myeloid Leukemia Market by Drug Class
9.5.5.1.2 Brazil Acute Myeloid Leukemia Market by End Use
9.5.5.2 Argentina Acute Myeloid Leukemia Market
9.5.5.2.1 Argentina Acute Myeloid Leukemia Market by Drug Class
9.5.5.2.2 Argentina Acute Myeloid Leukemia Market by End Use
9.5.5.3 Rest of South and Central America Acute Myeloid Leukemia Market
9.5.5.3.1 Rest of South and Central America Acute Myeloid Leukemia Market by Drug Class
9.5.5.3.2 Rest of South and Central America Acute Myeloid Leukemia Market by End Use
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ACUTE MYELOID LEUKEMIA MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ACUTE MYELOID LEUKEMIA MARKET, KEY COMPANY PROFILES
12.1. JOHNSON AND JOHNSON PRIVATE LIMITED
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PFIZER INC
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ABBOTT
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ASTRAZENECA
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. BAYER
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. CELGENE CORPORATION
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. AMBIT BIOSCIENCES CORPORATION
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. CYCLACEL PHARMACEUTICALS INC
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. NOVARTIS AG
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SANOFI
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Johnson & Johnson Private Limited
2. Pfizer Inc
3. Abbott
4. AstraZeneca
5. Bayer
6. Celgene Corporation
7. Ambit Biosciences Corporation
8. Cyclacel Pharmaceuticals Inc
9. Novartis AG
10. Sanofi
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For